The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.d

Myocarditis (can be fulminant)

Publications

Li MT, He Y, Huang SY, Hu X, Chen JS

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.

Investigational new drugs. 2024;42(1):116-126

Fazal M, Prentice DA, Kho LK, Fysh E

Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.

Internal medicine journal. 2020;50(8):1003-1006

Yamaguchi S, Morimoto R, Okumura T, Yamashita Y, Haga T, Kuwayama T, Yokoi T, Hiraiwa H, Kondo T, Sugiura Y, Watanabe N, Kano N, Kohno K, Fukaya K, Sawamura A, Yokota K, Ishii H, Nakaguro M, Akiyama M, Murohara T

Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.

The Canadian journal of cardiology. 2018;34(6):812.e1-812.e3

Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM

Smoldering myocarditis following immune checkpoint blockade.

Journal for immunotherapy of cancer. 2017;5(1):91

Matson DR, Accola MA, Rehrauer WM, Corliss RF

Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab.

Journal of forensic sciences. 2018;63(3):954-957

Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.

Neurology. 2017;89(11):1127-1134

Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohé C

Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.

Lung cancer (Amsterdam, Netherlands). 2016;99:117-9

Gibson R, Delaune J, Szady A, Markham M

Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.

BMJ case reports. 2016;2016